Condition: Triple Negative Breast Cancer (TNBC) · Sponsor: Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
CIRCADIAN is a prospective randomized clinical trial designed to evaluate the impact of pembrolizumab infusions' time-of-day on pathological complete response (pCR) rate among TNBC patients undergoing neoadjuvant treatment.
This description comes directly from the study's public registry record.
Alexandra P. Guedes, Medical Oncologist M.D. · +351968957977 · alexandra95dg@gmail.com
Always discuss trial participation with your own doctor first.
| Centro Hospitalar Vila Nova de Gaia/Espinho | Vila Nova de Gaia, Região, Portugal | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06880029